Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)

ClinicalTrials.gov ID: NCT00326417

Public ClinicalTrials.gov record NCT00326417. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Fludarabine-based Conditioning for Allogeneic Marrow Transplantation From HLA-compatible Unrelated Donors in Severe Aplastic Anemia (BMT CTN #0301)

Study identification

NCT ID: NCT00326417
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Medical College of Wisconsin; Other
Enrollment: 97 participants

Conditions and interventions

Conditions

Anemia, Aplastic

Interventions

Fludarabine Drug
Cyclophosphamide 150mg Drug
Cyclophosphamide 100mg Drug
Cyclophosphamide 50mg Drug

Drug

Eligibility (public fields only)

Age range: Up to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 31, 2005
Primary completion: Aug 31, 2015
Completion: Dec 31, 2015
Last update posted: Oct 27, 2021

2006 – 2016

United States locations

U.S. sites: 22
U.S. states: 15
U.S. cities: 20

Facility	City	State	ZIP	Site status
Phoenix Children's Hospital	Phoenix	Arizona	85016	—
City of Hope National Medical Center	Duarte	California	91010	—
Children's Hospital Los Angeles	Los Angeles	California	90027	—
Mattel Children's Hospital at UCLA	Los Angeles	California	90095	—
Stanford Hospital and Clinics	Stanford	California	94305	—
H. Lee Moffitt Cancer Center	Tampa	Florida	33624	—
Children's Healthcare of Atlanta	Atlanta	Georgia	30322	—
BMT Program at Northside Hospital	Atlanta	Georgia	30342	—
DFCI/Brigham & Women's Hospital	Boston	Massachusetts	02114	—
University of Michigan	Ann Arbor	Michigan	48109	—
University of Minnesota	Minneapolis	Minnesota	55455	—
Hackensack University Medical Center	Hackensack	New Jersey	07601	—
Roswell Park Cancer Institute	Buffalo	New York	14263	—
Memorial Sloan-Kettering Cancer Center	New York	New York	10021	—
Duke University Medical Center	Durham	North Carolina	27705	—
Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio	45229	—
Oregon Health & Science University	Portland	Oregon	97239-3098	—
Cook Children's Medical Center	Fort Worth	Texas	76104	—
University of Texas, MD Anderson CRC	Houston	Texas	77030	—
Texas Transplant Institute	San Antonio	Texas	78229	—
Virginia Commonwealth University, MCV Hospital	Richmond	Virginia	23298	—
Fred Hutchinson Cancer Research Center	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00326417, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 27, 2021 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00326417 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →